nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CBR1—Doxorubicin—muscle cancer	0.343	0.411	CbGbCtD
Haloperidol—CYP1A1—Dacarbazine—muscle cancer	0.107	0.129	CbGbCtD
Haloperidol—CYP1A2—Dacarbazine—muscle cancer	0.048	0.0576	CbGbCtD
Haloperidol—CYP3A7—Vincristine—muscle cancer	0.0459	0.0551	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0459	0.0551	CbGbCtD
Haloperidol—ABCB1—Dactinomycin—muscle cancer	0.0364	0.0437	CbGbCtD
Haloperidol—CYP3A5—Vincristine—muscle cancer	0.0345	0.0413	CbGbCtD
Haloperidol—CYP3A5—Etoposide—muscle cancer	0.0316	0.0379	CbGbCtD
Haloperidol—CYP1A2—Etoposide—muscle cancer	0.0235	0.0282	CbGbCtD
Haloperidol—ABCB1—Vincristine—muscle cancer	0.0224	0.0269	CbGbCtD
Haloperidol—ABCB1—Etoposide—muscle cancer	0.0205	0.0246	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—muscle cancer	0.014	0.0168	CbGbCtD
Haloperidol—ABCB1—Methotrexate—muscle cancer	0.0136	0.0163	CbGbCtD
Haloperidol—CYP3A4—Vincristine—muscle cancer	0.0134	0.0161	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—muscle cancer	0.0132	0.0158	CbGbCtD
Haloperidol—CYP3A4—Etoposide—muscle cancer	0.0123	0.0148	CbGbCtD
Haloperidol—CYP3A4—Doxorubicin—muscle cancer	0.0084	0.0101	CbGbCtD
Haloperidol—HTR2A—hindlimb—muscle cancer	0.00215	0.0408	CbGeAlD
Haloperidol—UGT1A9—renal system—muscle cancer	0.00196	0.0371	CbGeAlD
Haloperidol—HTR2A—appendage—muscle cancer	0.00185	0.035	CbGeAlD
Haloperidol—H1F0—embryo—muscle cancer	0.00159	0.0302	CbGeAlD
Haloperidol—DRD4—testis—muscle cancer	0.00153	0.029	CbGeAlD
Haloperidol—CBR1—renal system—muscle cancer	0.00147	0.0279	CbGeAlD
Haloperidol—GRIN2B—head—muscle cancer	0.00133	0.0252	CbGeAlD
Haloperidol—CBR1—cardiac atrium—muscle cancer	0.00132	0.025	CbGeAlD
Haloperidol—H1F0—smooth muscle tissue—muscle cancer	0.00125	0.0238	CbGeAlD
Haloperidol—H1F0—renal system—muscle cancer	0.00121	0.0229	CbGeAlD
Haloperidol—CBR1—tendon—muscle cancer	0.00115	0.0218	CbGeAlD
Haloperidol—CBR1—bone marrow—muscle cancer	0.00111	0.0211	CbGeAlD
Haloperidol—DRD3—head—muscle cancer	0.00111	0.0211	CbGeAlD
Haloperidol—H1F0—cardiac atrium—muscle cancer	0.00108	0.0205	CbGeAlD
Haloperidol—CBR1—vagina—muscle cancer	0.00107	0.0202	CbGeAlD
Haloperidol—CBR1—head—muscle cancer	0.000985	0.0187	CbGeAlD
Haloperidol—CBR1—testis—muscle cancer	0.000952	0.0181	CbGeAlD
Haloperidol—H1F0—tendon—muscle cancer	0.000942	0.0179	CbGeAlD
Haloperidol—H1F0—bone marrow—muscle cancer	0.000912	0.0173	CbGeAlD
Haloperidol—SIGMAR1—smooth muscle tissue—muscle cancer	0.000905	0.0172	CbGeAlD
Haloperidol—HTR2B—smooth muscle tissue—muscle cancer	0.000903	0.0171	CbGeAlD
Haloperidol—H1F0—vagina—muscle cancer	0.000874	0.0166	CbGeAlD
Haloperidol—H1F0—head—muscle cancer	0.000807	0.0153	CbGeAlD
Haloperidol—DRD1—head—muscle cancer	0.000797	0.0151	CbGeAlD
Haloperidol—SIGMAR1—cardiac atrium—muscle cancer	0.000781	0.0148	CbGeAlD
Haloperidol—H1F0—testis—muscle cancer	0.00078	0.0148	CbGeAlD
Haloperidol—Nystagmus—Doxorubicin—muscle cancer	0.000694	0.00636	CcSEcCtD
Haloperidol—KCNH2—renal system—muscle cancer	0.000694	0.0132	CbGeAlD
Haloperidol—Neutropenia—Vincristine—muscle cancer	0.000693	0.00634	CcSEcCtD
Haloperidol—Agranulocytosis—Dactinomycin—muscle cancer	0.00069	0.00631	CcSEcCtD
Haloperidol—Erectile dysfunction—Vincristine—muscle cancer	0.000682	0.00624	CcSEcCtD
Haloperidol—SIGMAR1—tendon—muscle cancer	0.00068	0.0129	CbGeAlD
Haloperidol—HTR2B—tendon—muscle cancer	0.000679	0.0129	CbGeAlD
Haloperidol—Photosensitivity reaction—Vincristine—muscle cancer	0.000676	0.00619	CcSEcCtD
Haloperidol—Ventricular arrhythmia—Doxorubicin—muscle cancer	0.00067	0.00613	CcSEcCtD
Haloperidol—Weight decreased—Vincristine—muscle cancer	0.00067	0.00613	CcSEcCtD
Haloperidol—Hepatitis—Dactinomycin—muscle cancer	0.000664	0.00607	CcSEcCtD
Haloperidol—Cardiac arrest—Etoposide—muscle cancer	0.00066	0.00604	CcSEcCtD
Haloperidol—SIGMAR1—bone marrow—muscle cancer	0.000659	0.0125	CbGeAlD
Haloperidol—Depression—Vincristine—muscle cancer	0.000659	0.00603	CcSEcCtD
Haloperidol—HTR1B—head—muscle cancer	0.000646	0.0123	CbGeAlD
Haloperidol—Musculoskeletal stiffness—Methotrexate—muscle cancer	0.000639	0.00584	CcSEcCtD
Haloperidol—SIGMAR1—vagina—muscle cancer	0.000631	0.012	CbGeAlD
Haloperidol—HTR2B—vagina—muscle cancer	0.00063	0.0119	CbGeAlD
Haloperidol—HTR1D—head—muscle cancer	0.000625	0.0119	CbGeAlD
Haloperidol—KCNH2—cardiac atrium—muscle cancer	0.000621	0.0118	CbGeAlD
Haloperidol—HTR2A—embryo—muscle cancer	0.000613	0.0116	CbGeAlD
Haloperidol—Dysphagia—Etoposide—muscle cancer	0.0006	0.00549	CcSEcCtD
Haloperidol—CYP1A2—renal system—muscle cancer	0.000594	0.0113	CbGeAlD
Haloperidol—Bronchospasm—Etoposide—muscle cancer	0.00059	0.0054	CcSEcCtD
Haloperidol—Hallucination—Vincristine—muscle cancer	0.00059	0.0054	CcSEcCtD
Haloperidol—Alopecia—Dactinomycin—muscle cancer	0.000586	0.00537	CcSEcCtD
Haloperidol—CYP1A1—renal system—muscle cancer	0.000586	0.0111	CbGeAlD
Haloperidol—Urinary tract disorder—Vincristine—muscle cancer	0.000586	0.00536	CcSEcCtD
Haloperidol—Sweating increased—Etoposide—muscle cancer	0.000585	0.00535	CcSEcCtD
Haloperidol—Connective tissue disorder—Vincristine—muscle cancer	0.000583	0.00533	CcSEcCtD
Haloperidol—HTR2B—head—muscle cancer	0.000582	0.011	CbGeAlD
Haloperidol—Urethral disorder—Vincristine—muscle cancer	0.000581	0.00532	CcSEcCtD
Haloperidol—HRH1—smooth muscle tissue—muscle cancer	0.000578	0.011	CbGeAlD
Haloperidol—CYP3A5—renal system—muscle cancer	0.000573	0.0109	CbGeAlD
Haloperidol—Pancytopenia—Etoposide—muscle cancer	0.00057	0.00521	CcSEcCtD
Haloperidol—Breast pain—Doxorubicin—muscle cancer	0.000569	0.0052	CcSEcCtD
Haloperidol—Amenorrhoea—Doxorubicin—muscle cancer	0.000565	0.00517	CcSEcCtD
Haloperidol—SIGMAR1—testis—muscle cancer	0.000563	0.0107	CbGeAlD
Haloperidol—Neutropenia—Etoposide—muscle cancer	0.000561	0.00513	CcSEcCtD
Haloperidol—Cardiac disorder—Vincristine—muscle cancer	0.00055	0.00504	CcSEcCtD
Haloperidol—Angiopathy—Vincristine—muscle cancer	0.000538	0.00492	CcSEcCtD
Haloperidol—Mediastinal disorder—Vincristine—muscle cancer	0.000534	0.00489	CcSEcCtD
Haloperidol—Anaemia—Dactinomycin—muscle cancer	0.000534	0.00489	CcSEcCtD
Haloperidol—Dyskinesia—Doxorubicin—muscle cancer	0.000528	0.00483	CcSEcCtD
Haloperidol—CYP2C19—vagina—muscle cancer	0.000527	0.00999	CbGeAlD
Haloperidol—CYP1A1—cardiac atrium—muscle cancer	0.000525	0.00995	CbGeAlD
Haloperidol—KCNH2—bone marrow—muscle cancer	0.000524	0.00995	CbGeAlD
Haloperidol—Alopecia—Vincristine—muscle cancer	0.000524	0.00479	CcSEcCtD
Haloperidol—Jaundice—Etoposide—muscle cancer	0.000522	0.00477	CcSEcCtD
Haloperidol—Mental disorder—Vincristine—muscle cancer	0.000519	0.00475	CcSEcCtD
Haloperidol—Leukopenia—Dactinomycin—muscle cancer	0.000517	0.00473	CcSEcCtD
Haloperidol—Gynaecomastia—Methotrexate—muscle cancer	0.000513	0.00469	CcSEcCtD
Haloperidol—Gait disturbance—Doxorubicin—muscle cancer	0.000508	0.00465	CcSEcCtD
Haloperidol—Hepatobiliary disease—Etoposide—muscle cancer	0.000506	0.00463	CcSEcCtD
Haloperidol—KCNH2—vagina—muscle cancer	0.000502	0.00953	CbGeAlD
Haloperidol—Agranulocytosis—Etoposide—muscle cancer	0.000499	0.00457	CcSEcCtD
Haloperidol—Ventricular tachycardia—Doxorubicin—muscle cancer	0.000496	0.00454	CcSEcCtD
Haloperidol—Injection site reaction—Doxorubicin—muscle cancer	0.000493	0.00451	CcSEcCtD
Haloperidol—HTR2A—smooth muscle tissue—muscle cancer	0.000482	0.00915	CbGeAlD
Haloperidol—Salivary hypersecretion—Doxorubicin—muscle cancer	0.000482	0.00441	CcSEcCtD
Haloperidol—Anaemia—Vincristine—muscle cancer	0.000477	0.00437	CcSEcCtD
Haloperidol—Urinary tract disorder—Etoposide—muscle cancer	0.000474	0.00434	CcSEcCtD
Haloperidol—Agitation—Vincristine—muscle cancer	0.000474	0.00434	CcSEcCtD
Haloperidol—Photosensitivity—Methotrexate—muscle cancer	0.000474	0.00433	CcSEcCtD
Haloperidol—Oedema—Dactinomycin—muscle cancer	0.000471	0.00431	CcSEcCtD
Haloperidol—DRD2—head—muscle cancer	0.000471	0.00893	CbGeAlD
Haloperidol—Urethral disorder—Etoposide—muscle cancer	0.000471	0.00431	CcSEcCtD
Haloperidol—HTR2A—renal system—muscle cancer	0.000464	0.00881	CbGeAlD
Haloperidol—KCNH2—head—muscle cancer	0.000464	0.0088	CbGeAlD
Haloperidol—Vertigo—Vincristine—muscle cancer	0.000464	0.00424	CcSEcCtD
Haloperidol—Leukopenia—Vincristine—muscle cancer	0.000462	0.00423	CcSEcCtD
Haloperidol—Thrombocytopenia—Dactinomycin—muscle cancer	0.000462	0.00422	CcSEcCtD
Haloperidol—DRD2—testis—muscle cancer	0.000455	0.00863	CbGeAlD
Haloperidol—Anorexia—Dactinomycin—muscle cancer	0.000449	0.00411	CcSEcCtD
Haloperidol—Eye disorder—Etoposide—muscle cancer	0.000449	0.00411	CcSEcCtD
Haloperidol—KCNH2—testis—muscle cancer	0.000448	0.0085	CbGeAlD
Haloperidol—Convulsion—Vincristine—muscle cancer	0.000447	0.00409	CcSEcCtD
Haloperidol—Cardiac disorder—Etoposide—muscle cancer	0.000446	0.00408	CcSEcCtD
Haloperidol—Hypertension—Vincristine—muscle cancer	0.000446	0.00408	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Methotrexate—muscle cancer	0.000441	0.00403	CcSEcCtD
Haloperidol—Visual disturbance—Methotrexate—muscle cancer	0.000439	0.00402	CcSEcCtD
Haloperidol—Angiopathy—Etoposide—muscle cancer	0.000436	0.00399	CcSEcCtD
Haloperidol—Hypertonia—Doxorubicin—muscle cancer	0.000435	0.00398	CcSEcCtD
Haloperidol—HRH1—tendon—muscle cancer	0.000434	0.00823	CbGeAlD
Haloperidol—Immune system disorder—Etoposide—muscle cancer	0.000434	0.00397	CcSEcCtD
Haloperidol—Mediastinal disorder—Etoposide—muscle cancer	0.000433	0.00396	CcSEcCtD
Haloperidol—CYP3A4—renal system—muscle cancer	0.00043	0.00815	CbGeAlD
Haloperidol—Alopecia—Etoposide—muscle cancer	0.000424	0.00388	CcSEcCtD
Haloperidol—Lethargy—Methotrexate—muscle cancer	0.000424	0.00388	CcSEcCtD
Haloperidol—CYP1A1—vagina—muscle cancer	0.000424	0.00805	CbGeAlD
Haloperidol—CYP2D6—renal system—muscle cancer	0.000423	0.00802	CbGeAlD
Haloperidol—Oedema—Vincristine—muscle cancer	0.000421	0.00385	CcSEcCtD
Haloperidol—Anaphylactic shock—Vincristine—muscle cancer	0.000421	0.00385	CcSEcCtD
Haloperidol—CYP3A5—vagina—muscle cancer	0.000415	0.00787	CbGeAlD
Haloperidol—Nervous system disorder—Vincristine—muscle cancer	0.000413	0.00378	CcSEcCtD
Haloperidol—Thrombocytopenia—Vincristine—muscle cancer	0.000412	0.00377	CcSEcCtD
Haloperidol—Hepatic function abnormal—Doxorubicin—muscle cancer	0.000412	0.00377	CcSEcCtD
Haloperidol—Photosensitivity—Doxorubicin—muscle cancer	0.00041	0.00375	CcSEcCtD
Haloperidol—Decreased appetite—Dactinomycin—muscle cancer	0.00041	0.00375	CcSEcCtD
Haloperidol—Hyperhidrosis—Vincristine—muscle cancer	0.000407	0.00373	CcSEcCtD
Haloperidol—HRH1—vagina—muscle cancer	0.000403	0.00764	CbGeAlD
Haloperidol—ABCB1—embryo—muscle cancer	0.000402	0.00763	CbGeAlD
Haloperidol—Muscle spasms—Etoposide—muscle cancer	0.000402	0.00368	CcSEcCtD
Haloperidol—Anorexia—Vincristine—muscle cancer	0.000402	0.00367	CcSEcCtD
Haloperidol—Hypotension—Vincristine—muscle cancer	0.000394	0.0036	CcSEcCtD
Haloperidol—CYP1A1—head—muscle cancer	0.000392	0.00743	CbGeAlD
Haloperidol—Feeling abnormal—Dactinomycin—muscle cancer	0.000389	0.00356	CcSEcCtD
Haloperidol—Anaemia—Etoposide—muscle cancer	0.000386	0.00354	CcSEcCtD
Haloperidol—Liver function test abnormal—Methotrexate—muscle cancer	0.000384	0.00351	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.000382	0.00349	CcSEcCtD
Haloperidol—Insomnia—Vincristine—muscle cancer	0.000381	0.00349	CcSEcCtD
Haloperidol—Breast disorder—Methotrexate—muscle cancer	0.000376	0.00344	CcSEcCtD
Haloperidol—Vertigo—Etoposide—muscle cancer	0.000376	0.00344	CcSEcCtD
Haloperidol—Leukopenia—Etoposide—muscle cancer	0.000374	0.00342	CcSEcCtD
Haloperidol—Body temperature increased—Dactinomycin—muscle cancer	0.000373	0.00341	CcSEcCtD
Haloperidol—HRH1—head—muscle cancer	0.000372	0.00706	CbGeAlD
Haloperidol—Hypoglycaemia—Doxorubicin—muscle cancer	0.000369	0.00338	CcSEcCtD
Haloperidol—Lethargy—Doxorubicin—muscle cancer	0.000367	0.00336	CcSEcCtD
Haloperidol—Decreased appetite—Vincristine—muscle cancer	0.000366	0.00335	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Vincristine—muscle cancer	0.000364	0.00333	CcSEcCtD
Haloperidol—HTR2A—tendon—muscle cancer	0.000362	0.00687	CbGeAlD
Haloperidol—Convulsion—Etoposide—muscle cancer	0.000362	0.00332	CcSEcCtD
Haloperidol—Hyponatraemia—Doxorubicin—muscle cancer	0.000362	0.00331	CcSEcCtD
Haloperidol—Hypertension—Etoposide—muscle cancer	0.000361	0.0033	CcSEcCtD
Haloperidol—Constipation—Vincristine—muscle cancer	0.00036	0.0033	CcSEcCtD
Haloperidol—HRH1—testis—muscle cancer	0.000359	0.00682	CbGeAlD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000354	0.00324	CcSEcCtD
Haloperidol—Face oedema—Doxorubicin—muscle cancer	0.000348	0.00318	CcSEcCtD
Haloperidol—Hypersensitivity—Dactinomycin—muscle cancer	0.000347	0.00318	CcSEcCtD
Haloperidol—Confusional state—Etoposide—muscle cancer	0.000344	0.00315	CcSEcCtD
Haloperidol—Cardiac arrest—Doxorubicin—muscle cancer	0.000342	0.00313	CcSEcCtD
Haloperidol—Pancytopenia—Methotrexate—muscle cancer	0.000341	0.00312	CcSEcCtD
Haloperidol—Anaphylactic shock—Etoposide—muscle cancer	0.000341	0.00312	CcSEcCtD
Haloperidol—HTR2A—vagina—muscle cancer	0.000336	0.00638	CbGeAlD
Haloperidol—Neutropenia—Methotrexate—muscle cancer	0.000336	0.00308	CcSEcCtD
Haloperidol—Thrombocytopenia—Etoposide—muscle cancer	0.000334	0.00306	CcSEcCtD
Haloperidol—Tachycardia—Etoposide—muscle cancer	0.000333	0.00305	CcSEcCtD
Haloperidol—Body temperature increased—Vincristine—muscle cancer	0.000333	0.00305	CcSEcCtD
Haloperidol—Liver function test abnormal—Doxorubicin—muscle cancer	0.000332	0.00304	CcSEcCtD
Haloperidol—Skin disorder—Etoposide—muscle cancer	0.000331	0.00303	CcSEcCtD
Haloperidol—Erectile dysfunction—Methotrexate—muscle cancer	0.000331	0.00303	CcSEcCtD
Haloperidol—Hyperhidrosis—Etoposide—muscle cancer	0.00033	0.00302	CcSEcCtD
Haloperidol—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000329	0.00301	CcSEcCtD
Haloperidol—Photosensitivity reaction—Methotrexate—muscle cancer	0.000328	0.003	CcSEcCtD
Haloperidol—Breast disorder—Doxorubicin—muscle cancer	0.000325	0.00298	CcSEcCtD
Haloperidol—Anorexia—Etoposide—muscle cancer	0.000325	0.00298	CcSEcCtD
Haloperidol—Diarrhoea—Dactinomycin—muscle cancer	0.000323	0.00295	CcSEcCtD
Haloperidol—Drowsiness—Methotrexate—muscle cancer	0.00032	0.00293	CcSEcCtD
Haloperidol—Depression—Methotrexate—muscle cancer	0.00032	0.00292	CcSEcCtD
Haloperidol—Hypotension—Etoposide—muscle cancer	0.000319	0.00292	CcSEcCtD
Haloperidol—Dysphagia—Doxorubicin—muscle cancer	0.000311	0.00285	CcSEcCtD
Haloperidol—HTR2A—head—muscle cancer	0.000311	0.00589	CbGeAlD
Haloperidol—Hypersensitivity—Vincristine—muscle cancer	0.00031	0.00284	CcSEcCtD
Haloperidol—ABCB1—renal system—muscle cancer	0.000304	0.00577	CbGeAlD
Haloperidol—Dyspnoea—Etoposide—muscle cancer	0.000304	0.00278	CcSEcCtD
Haloperidol—Somnolence—Etoposide—muscle cancer	0.000303	0.00278	CcSEcCtD
Haloperidol—Hepatobiliary disease—Methotrexate—muscle cancer	0.000303	0.00277	CcSEcCtD
Haloperidol—HTR2A—testis—muscle cancer	0.0003	0.00569	CbGeAlD
Haloperidol—Vomiting—Dactinomycin—muscle cancer	0.0003	0.00274	CcSEcCtD
Haloperidol—Agranulocytosis—Methotrexate—muscle cancer	0.000299	0.00274	CcSEcCtD
Haloperidol—Rash—Dactinomycin—muscle cancer	0.000297	0.00272	CcSEcCtD
Haloperidol—Decreased appetite—Etoposide—muscle cancer	0.000297	0.00271	CcSEcCtD
Haloperidol—Pancytopenia—Doxorubicin—muscle cancer	0.000296	0.0027	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Etoposide—muscle cancer	0.000295	0.0027	CcSEcCtD
Haloperidol—Constipation—Etoposide—muscle cancer	0.000292	0.00267	CcSEcCtD
Haloperidol—Neutropenia—Doxorubicin—muscle cancer	0.000291	0.00266	CcSEcCtD
Haloperidol—Diarrhoea—Vincristine—muscle cancer	0.000288	0.00264	CcSEcCtD
Haloperidol—Hepatitis—Methotrexate—muscle cancer	0.000288	0.00263	CcSEcCtD
Haloperidol—Urinary tract disorder—Methotrexate—muscle cancer	0.000284	0.0026	CcSEcCtD
Haloperidol—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000284	0.0026	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—muscle cancer	0.000283	0.00259	CcSEcCtD
Haloperidol—CYP2D6—head—muscle cancer	0.000283	0.00537	CbGeAlD
Haloperidol—Urethral disorder—Methotrexate—muscle cancer	0.000282	0.00258	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—muscle cancer	0.000282	0.00258	CcSEcCtD
Haloperidol—Feeling abnormal—Etoposide—muscle cancer	0.000281	0.00257	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—muscle cancer	0.000281	0.00257	CcSEcCtD
Haloperidol—Nausea—Dactinomycin—muscle cancer	0.00028	0.00256	CcSEcCtD
Haloperidol—Dizziness—Vincristine—muscle cancer	0.000279	0.00255	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—muscle cancer	0.000278	0.00254	CcSEcCtD
Haloperidol—Visual impairment—Methotrexate—muscle cancer	0.000277	0.00254	CcSEcCtD
Haloperidol—CYP2D6—testis—muscle cancer	0.000273	0.00519	CbGeAlD
Haloperidol—Urticaria—Etoposide—muscle cancer	0.000271	0.00248	CcSEcCtD
Haloperidol—Jaundice—Doxorubicin—muscle cancer	0.00027	0.00248	CcSEcCtD
Haloperidol—Body temperature increased—Etoposide—muscle cancer	0.00027	0.00247	CcSEcCtD
Haloperidol—Eye disorder—Methotrexate—muscle cancer	0.000269	0.00246	CcSEcCtD
Haloperidol—Vomiting—Vincristine—muscle cancer	0.000268	0.00245	CcSEcCtD
Haloperidol—Cardiac disorder—Methotrexate—muscle cancer	0.000267	0.00244	CcSEcCtD
Haloperidol—Rash—Vincristine—muscle cancer	0.000266	0.00243	CcSEcCtD
Haloperidol—Dermatitis—Vincristine—muscle cancer	0.000265	0.00243	CcSEcCtD
Haloperidol—Headache—Vincristine—muscle cancer	0.000264	0.00241	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000262	0.0024	CcSEcCtD
Haloperidol—Angiopathy—Methotrexate—muscle cancer	0.000261	0.00239	CcSEcCtD
Haloperidol—Immune system disorder—Methotrexate—muscle cancer	0.00026	0.00238	CcSEcCtD
Haloperidol—Mediastinal disorder—Methotrexate—muscle cancer	0.000259	0.00237	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—muscle cancer	0.000259	0.00237	CcSEcCtD
Haloperidol—Alopecia—Methotrexate—muscle cancer	0.000254	0.00233	CcSEcCtD
Haloperidol—Mental disorder—Methotrexate—muscle cancer	0.000252	0.00231	CcSEcCtD
Haloperidol—Hypersensitivity—Etoposide—muscle cancer	0.000251	0.0023	CcSEcCtD
Haloperidol—Malnutrition—Methotrexate—muscle cancer	0.00025	0.00229	CcSEcCtD
Haloperidol—Nausea—Vincristine—muscle cancer	0.00025	0.00229	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—muscle cancer	0.000249	0.00228	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—muscle cancer	0.000246	0.00225	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—muscle cancer	0.000245	0.00224	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—muscle cancer	0.000244	0.00223	CcSEcCtD
Haloperidol—Pruritus—Etoposide—muscle cancer	0.000241	0.00221	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—muscle cancer	0.00024	0.0022	CcSEcCtD
Haloperidol—Vision blurred—Methotrexate—muscle cancer	0.000236	0.00216	CcSEcCtD
Haloperidol—Diarrhoea—Etoposide—muscle cancer	0.000233	0.00214	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—muscle cancer	0.000233	0.00213	CcSEcCtD
Haloperidol—Anaemia—Methotrexate—muscle cancer	0.000231	0.00212	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—muscle cancer	0.000231	0.00212	CcSEcCtD
Haloperidol—ABCB1—bone marrow—muscle cancer	0.00023	0.00436	CbGeAlD
Haloperidol—Angiopathy—Doxorubicin—muscle cancer	0.000226	0.00207	CcSEcCtD
Haloperidol—Dizziness—Etoposide—muscle cancer	0.000226	0.00206	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—muscle cancer	0.000225	0.00206	CcSEcCtD
Haloperidol—Vertigo—Methotrexate—muscle cancer	0.000225	0.00206	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—muscle cancer	0.000225	0.00205	CcSEcCtD
Haloperidol—Leukopenia—Methotrexate—muscle cancer	0.000224	0.00205	CcSEcCtD
Haloperidol—ABCB1—vagina—muscle cancer	0.00022	0.00418	CbGeAlD
Haloperidol—Alopecia—Doxorubicin—muscle cancer	0.00022	0.00201	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—muscle cancer	0.000218	0.002	CcSEcCtD
Haloperidol—Convulsion—Methotrexate—muscle cancer	0.000217	0.00199	CcSEcCtD
Haloperidol—Vomiting—Etoposide—muscle cancer	0.000217	0.00199	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—muscle cancer	0.000217	0.00198	CcSEcCtD
Haloperidol—Rash—Etoposide—muscle cancer	0.000215	0.00197	CcSEcCtD
Haloperidol—Dermatitis—Etoposide—muscle cancer	0.000215	0.00197	CcSEcCtD
Haloperidol—Headache—Etoposide—muscle cancer	0.000214	0.00196	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000212	0.00194	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—muscle cancer	0.000208	0.00191	CcSEcCtD
Haloperidol—Confusional state—Methotrexate—muscle cancer	0.000206	0.00189	CcSEcCtD
Haloperidol—Anaphylactic shock—Methotrexate—muscle cancer	0.000204	0.00187	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—muscle cancer	0.000204	0.00187	CcSEcCtD
Haloperidol—ABCB1—head—muscle cancer	0.000204	0.00386	CbGeAlD
Haloperidol—Nausea—Etoposide—muscle cancer	0.000203	0.00185	CcSEcCtD
Haloperidol—Nervous system disorder—Methotrexate—muscle cancer	0.0002	0.00183	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—muscle cancer	0.0002	0.00183	CcSEcCtD
Haloperidol—Thrombocytopenia—Methotrexate—muscle cancer	0.0002	0.00183	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—muscle cancer	0.000199	0.00182	CcSEcCtD
Haloperidol—Skin disorder—Methotrexate—muscle cancer	0.000199	0.00182	CcSEcCtD
Haloperidol—Hyperhidrosis—Methotrexate—muscle cancer	0.000198	0.00181	CcSEcCtD
Haloperidol—ABCB1—testis—muscle cancer	0.000197	0.00373	CbGeAlD
Haloperidol—Vertigo—Doxorubicin—muscle cancer	0.000195	0.00178	CcSEcCtD
Haloperidol—Anorexia—Methotrexate—muscle cancer	0.000195	0.00178	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—muscle cancer	0.000194	0.00178	CcSEcCtD
Haloperidol—Hypotension—Methotrexate—muscle cancer	0.000191	0.00175	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—muscle cancer	0.000188	0.00172	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—muscle cancer	0.000187	0.00171	CcSEcCtD
Haloperidol—Insomnia—Methotrexate—muscle cancer	0.000185	0.00169	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—muscle cancer	0.000184	0.00168	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000183	0.00168	CcSEcCtD
Haloperidol—Dyspnoea—Methotrexate—muscle cancer	0.000182	0.00167	CcSEcCtD
Haloperidol—Somnolence—Methotrexate—muscle cancer	0.000182	0.00166	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—muscle cancer	0.000181	0.00165	CcSEcCtD
Haloperidol—Dyspepsia—Methotrexate—muscle cancer	0.00018	0.00165	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—muscle cancer	0.000178	0.00163	CcSEcCtD
Haloperidol—Decreased appetite—Methotrexate—muscle cancer	0.000178	0.00163	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—muscle cancer	0.000177	0.00162	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—muscle cancer	0.000177	0.00162	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000176	0.00161	CcSEcCtD
Haloperidol—Nervous system disorder—Doxorubicin—muscle cancer	0.000174	0.00159	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—muscle cancer	0.000173	0.00159	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—muscle cancer	0.000173	0.00158	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—muscle cancer	0.000172	0.00157	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—muscle cancer	0.000171	0.00157	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—muscle cancer	0.000169	0.00154	CcSEcCtD
Haloperidol—Feeling abnormal—Methotrexate—muscle cancer	0.000168	0.00154	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—muscle cancer	0.000165	0.00151	CcSEcCtD
Haloperidol—Urticaria—Methotrexate—muscle cancer	0.000162	0.00149	CcSEcCtD
Haloperidol—Body temperature increased—Methotrexate—muscle cancer	0.000162	0.00148	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—muscle cancer	0.00016	0.00146	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—muscle cancer	0.000158	0.00144	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—muscle cancer	0.000157	0.00144	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—muscle cancer	0.000156	0.00143	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—muscle cancer	0.000154	0.00141	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000153	0.0014	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—muscle cancer	0.000151	0.00139	CcSEcCtD
Haloperidol—Hypersensitivity—Methotrexate—muscle cancer	0.000151	0.00138	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—muscle cancer	0.000146	0.00133	CcSEcCtD
Haloperidol—Pruritus—Methotrexate—muscle cancer	0.000145	0.00132	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—muscle cancer	0.000141	0.00129	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—muscle cancer	0.00014	0.00128	CcSEcCtD
Haloperidol—Diarrhoea—Methotrexate—muscle cancer	0.00014	0.00128	CcSEcCtD
Haloperidol—Dizziness—Methotrexate—muscle cancer	0.000135	0.00124	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—muscle cancer	0.00013	0.00119	CcSEcCtD
Haloperidol—Vomiting—Methotrexate—muscle cancer	0.00013	0.00119	CcSEcCtD
Haloperidol—Rash—Methotrexate—muscle cancer	0.000129	0.00118	CcSEcCtD
Haloperidol—Dermatitis—Methotrexate—muscle cancer	0.000129	0.00118	CcSEcCtD
Haloperidol—Headache—Methotrexate—muscle cancer	0.000128	0.00117	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—muscle cancer	0.000125	0.00115	CcSEcCtD
Haloperidol—Nausea—Methotrexate—muscle cancer	0.000121	0.00111	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—muscle cancer	0.000121	0.00111	CcSEcCtD
Haloperidol—Dizziness—Doxorubicin—muscle cancer	0.000117	0.00107	CcSEcCtD
Haloperidol—Vomiting—Doxorubicin—muscle cancer	0.000113	0.00103	CcSEcCtD
Haloperidol—Rash—Doxorubicin—muscle cancer	0.000112	0.00102	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—muscle cancer	0.000111	0.00102	CcSEcCtD
Haloperidol—Headache—Doxorubicin—muscle cancer	0.000111	0.00101	CcSEcCtD
Haloperidol—Nausea—Doxorubicin—muscle cancer	0.000105	0.000962	CcSEcCtD
Haloperidol—HTR1B—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	1.69e-05	0.00421	CbGpPWpGaD
Haloperidol—EBP—Metabolism—MED12—muscle cancer	1.68e-05	0.00416	CbGpPWpGaD
Haloperidol—DRD4—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	1.67e-05	0.00414	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—MED12—muscle cancer	1.65e-05	0.00409	CbGpPWpGaD
Haloperidol—GRIN2B—Alzheimers Disease—TP53—muscle cancer	1.61e-05	0.00399	CbGpPWpGaD
Haloperidol—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	1.61e-05	0.00399	CbGpPWpGaD
Haloperidol—DRD3—G alpha (i) signalling events—CNR1—muscle cancer	1.6e-05	0.00396	CbGpPWpGaD
Haloperidol—HTR2B—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	1.59e-05	0.00395	CbGpPWpGaD
Haloperidol—CYP1A1—Tryptophan metabolism—MDM2—muscle cancer	1.57e-05	0.00391	CbGpPWpGaD
Haloperidol—EBP—Metabolism—ENO2—muscle cancer	1.53e-05	0.00379	CbGpPWpGaD
Haloperidol—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	1.52e-05	0.00377	CbGpPWpGaD
Haloperidol—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	1.52e-05	0.00377	CbGpPWpGaD
Haloperidol—H1F0—Apoptosis—TP53—muscle cancer	1.51e-05	0.00376	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—ENO2—muscle cancer	1.5e-05	0.00373	CbGpPWpGaD
Haloperidol—DRD1—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	1.5e-05	0.00373	CbGpPWpGaD
Haloperidol—HTR1D—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	1.48e-05	0.00368	CbGpPWpGaD
Haloperidol—DRD3—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	1.48e-05	0.00368	CbGpPWpGaD
Haloperidol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	1.45e-05	0.0036	CbGpPWpGaD
Haloperidol—DRD4—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	1.43e-05	0.00355	CbGpPWpGaD
Haloperidol—CYP1A1—Arachidonic acid metabolism—PTGS2—muscle cancer	1.42e-05	0.00353	CbGpPWpGaD
Haloperidol—HTR2B—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	1.36e-05	0.00339	CbGpPWpGaD
Haloperidol—HTR1D—GPCR ligand binding—PTCH1—muscle cancer	1.34e-05	0.00332	CbGpPWpGaD
Haloperidol—GRIN2B—Transmission across Chemical Synapses—MDM2—muscle cancer	1.33e-05	0.00331	CbGpPWpGaD
Haloperidol—HTR1B—GPCR ligand binding—PTCH1—muscle cancer	1.31e-05	0.00325	CbGpPWpGaD
Haloperidol—H1F0—Cellular responses to stress—VEGFA—muscle cancer	1.31e-05	0.00325	CbGpPWpGaD
Haloperidol—H1F0—Cellular Senescence—TP53—muscle cancer	1.31e-05	0.00325	CbGpPWpGaD
Haloperidol—DRD4—GPCR ligand binding—PTCH1—muscle cancer	1.29e-05	0.0032	CbGpPWpGaD
Haloperidol—DRD1—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	1.29e-05	0.00319	CbGpPWpGaD
Haloperidol—DRD3—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	1.27e-05	0.00315	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	1.24e-05	0.00309	CbGpPWpGaD
Haloperidol—HTR2B—GPCR ligand binding—PTCH1—muscle cancer	1.23e-05	0.00306	CbGpPWpGaD
Haloperidol—DRD2—G alpha (i) signalling events—CNR1—muscle cancer	1.22e-05	0.00303	CbGpPWpGaD
Haloperidol—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	1.2e-05	0.00297	CbGpPWpGaD
Haloperidol—EBP—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.19e-05	0.00297	CbGpPWpGaD
Haloperidol—CBR1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.18e-05	0.00292	CbGpPWpGaD
Haloperidol—CYP2C19—Arachidonic acid metabolism—PTGS2—muscle cancer	1.16e-05	0.00289	CbGpPWpGaD
Haloperidol—DRD1—GPCR ligand binding—PTCH1—muscle cancer	1.16e-05	0.00288	CbGpPWpGaD
Haloperidol—DRD3—GPCR ligand binding—PTCH1—muscle cancer	1.14e-05	0.00284	CbGpPWpGaD
Haloperidol—DRD2—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	1.13e-05	0.00281	CbGpPWpGaD
Haloperidol—HTR1D—GPCR ligand binding—CNR1—muscle cancer	1.13e-05	0.0028	CbGpPWpGaD
Haloperidol—HTR2A—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	1.11e-05	0.00277	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.11e-05	0.00276	CbGpPWpGaD
Haloperidol—HRH1—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	1.11e-05	0.00276	CbGpPWpGaD
Haloperidol—HTR1B—GPCR ligand binding—CNR1—muscle cancer	1.11e-05	0.00275	CbGpPWpGaD
Haloperidol—DRD4—GPCR ligand binding—CNR1—muscle cancer	1.09e-05	0.0027	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—FOXO1—muscle cancer	1.08e-05	0.00268	CbGpPWpGaD
Haloperidol—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	1.06e-05	0.00263	CbGpPWpGaD
Haloperidol—KCNH2—SIDS Susceptibility Pathways—VEGFA—muscle cancer	1.05e-05	0.00262	CbGpPWpGaD
Haloperidol—HTR2B—GPCR ligand binding—CNR1—muscle cancer	1.04e-05	0.00258	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KIDINS220—muscle cancer	1.03e-05	0.00256	CbGpPWpGaD
Haloperidol—GRIN2B—Neuronal System—MDM2—muscle cancer	1.02e-05	0.00254	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KIDINS220—muscle cancer	1.01e-05	0.0025	CbGpPWpGaD
Haloperidol—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	1e-05	0.00249	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KIDINS220—muscle cancer	9.92e-06	0.00246	CbGpPWpGaD
Haloperidol—H1F0—Cellular responses to stress—TP53—muscle cancer	9.88e-06	0.00245	CbGpPWpGaD
Haloperidol—DRD1—GPCR ligand binding—CNR1—muscle cancer	9.79e-06	0.00243	CbGpPWpGaD
Haloperidol—DRD2—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	9.71e-06	0.00241	CbGpPWpGaD
Haloperidol—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	9.68e-06	0.0024	CbGpPWpGaD
Haloperidol—DRD3—GPCR ligand binding—CNR1—muscle cancer	9.66e-06	0.0024	CbGpPWpGaD
Haloperidol—HTR2A—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	9.55e-06	0.00237	CbGpPWpGaD
Haloperidol—HRH1—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	9.53e-06	0.00237	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KIDINS220—muscle cancer	9.47e-06	0.00235	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	9.09e-06	0.00226	CbGpPWpGaD
Haloperidol—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	9.06e-06	0.00225	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KIDINS220—muscle cancer	8.93e-06	0.00222	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KIDINS220—muscle cancer	8.81e-06	0.00219	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—FH—muscle cancer	8.77e-06	0.00218	CbGpPWpGaD
Haloperidol—DRD2—GPCR ligand binding—PTCH1—muscle cancer	8.76e-06	0.00218	CbGpPWpGaD
Haloperidol—KCNH2—Neuronal System—MDM2—muscle cancer	8.72e-06	0.00217	CbGpPWpGaD
Haloperidol—HTR2A—GPCR ligand binding—PTCH1—muscle cancer	8.62e-06	0.00214	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—PTCH1—muscle cancer	8.6e-06	0.00214	CbGpPWpGaD
Haloperidol—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	7.75e-06	0.00193	CbGpPWpGaD
Haloperidol—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	7.63e-06	0.00189	CbGpPWpGaD
Haloperidol—DRD2—GPCR ligand binding—CNR1—muscle cancer	7.39e-06	0.00184	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—FH—muscle cancer	7.38e-06	0.00183	CbGpPWpGaD
Haloperidol—HTR2A—GPCR ligand binding—CNR1—muscle cancer	7.27e-06	0.00181	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—CNR1—muscle cancer	7.26e-06	0.0018	CbGpPWpGaD
Haloperidol—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	7.16e-06	0.00178	CbGpPWpGaD
Haloperidol—GRIN2B—Axon guidance—VEGFA—muscle cancer	6.88e-06	0.00171	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—PTCH1—muscle cancer	6.86e-06	0.0017	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KIDINS220—muscle cancer	6.74e-06	0.00168	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—PTCH1—muscle cancer	6.72e-06	0.00167	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KIDINS220—muscle cancer	6.64e-06	0.00165	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KIDINS220—muscle cancer	6.62e-06	0.00164	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—PTCH1—muscle cancer	6.61e-06	0.00164	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	6.39e-06	0.00159	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—CNR1—muscle cancer	6.38e-06	0.00158	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—PTCH1—muscle cancer	6.31e-06	0.00157	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—CNR1—muscle cancer	6.24e-06	0.00155	CbGpPWpGaD
Haloperidol—ABCB1—Allograft Rejection—VEGFA—muscle cancer	6.2e-06	0.00154	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—CNR1—muscle cancer	6.15e-06	0.00153	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—PTCH1—muscle cancer	5.95e-06	0.00148	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—PTCH1—muscle cancer	5.87e-06	0.00146	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—CNR1—muscle cancer	5.87e-06	0.00146	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—CNR1—muscle cancer	5.79e-06	0.00144	CbGpPWpGaD
Haloperidol—HTR2A—SIDS Susceptibility Pathways—VEGFA—muscle cancer	5.72e-06	0.00142	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—CNR1—muscle cancer	5.67e-06	0.00141	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—CNR1—muscle cancer	5.58e-06	0.00139	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—CNR1—muscle cancer	5.53e-06	0.00137	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—CNR1—muscle cancer	5.46e-06	0.00136	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—FH—muscle cancer	5.33e-06	0.00132	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—CNR1—muscle cancer	5.33e-06	0.00132	CbGpPWpGaD
Haloperidol—EBP—Metabolism—PTGS2—muscle cancer	5.32e-06	0.00132	CbGpPWpGaD
Haloperidol—DRD4—Circadian rythm related genes—TP53—muscle cancer	5.27e-06	0.00131	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—PTGS2—muscle cancer	5.23e-06	0.0013	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.23e-06	0.0013	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—FH—muscle cancer	5.04e-06	0.00125	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—CNR1—muscle cancer	5.02e-06	0.00125	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—CNR1—muscle cancer	4.96e-06	0.00123	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—MED12—muscle cancer	4.96e-06	0.00123	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—VEGFA—muscle cancer	4.91e-06	0.00122	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.77e-06	0.00118	CbGpPWpGaD
Haloperidol—DRD1—Circadian rythm related genes—TP53—muscle cancer	4.75e-06	0.00118	CbGpPWpGaD
Haloperidol—DRD3—Circadian rythm related genes—TP53—muscle cancer	4.68e-06	0.00116	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—ENO2—muscle cancer	4.52e-06	0.00112	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PTCH1—muscle cancer	4.49e-06	0.00112	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PTCH1—muscle cancer	4.42e-06	0.0011	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PTCH1—muscle cancer	4.41e-06	0.0011	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—CNR1—muscle cancer	4.18e-06	0.00104	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—MED12—muscle cancer	4.17e-06	0.00104	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—FH—muscle cancer	4.12e-06	0.00102	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—CNR1—muscle cancer	4.11e-06	0.00102	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—CNR1—muscle cancer	4.1e-06	0.00102	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.08e-06	0.00101	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PTCH1—muscle cancer	4.05e-06	0.00101	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	4.03e-06	0.001	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—FH—muscle cancer	4.02e-06	0.001	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PTCH1—muscle cancer	3.97e-06	0.000986	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PTCH1—muscle cancer	3.91e-06	0.00097	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	3.88e-06	0.000964	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—ENO2—muscle cancer	3.8e-06	0.000944	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CNR1—muscle cancer	3.79e-06	0.000942	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—FH—muscle cancer	3.79e-06	0.000942	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—FH—muscle cancer	3.76e-06	0.000934	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CNR1—muscle cancer	3.73e-06	0.000927	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PTCH1—muscle cancer	3.73e-06	0.000926	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CNR1—muscle cancer	3.72e-06	0.000925	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—TP53—muscle cancer	3.58e-06	0.00089	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.53e-06	0.000878	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PTCH1—muscle cancer	3.52e-06	0.000873	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—FOXO4—muscle cancer	3.49e-06	0.000866	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PTCH1—muscle cancer	3.47e-06	0.000862	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CNR1—muscle cancer	3.42e-06	0.00085	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—FOXO4—muscle cancer	3.41e-06	0.000848	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—FOXO4—muscle cancer	3.36e-06	0.000834	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CNR1—muscle cancer	3.35e-06	0.000832	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CNR1—muscle cancer	3.3e-06	0.000819	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—FH—muscle cancer	3.21e-06	0.000798	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—FOXO4—muscle cancer	3.21e-06	0.000796	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CNR1—muscle cancer	3.15e-06	0.000782	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	3.06e-06	0.00076	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—FOXO4—muscle cancer	3.02e-06	0.000751	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—MED12—muscle cancer	3.01e-06	0.000749	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—FOXO4—muscle cancer	2.98e-06	0.000741	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CNR1—muscle cancer	2.97e-06	0.000737	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CNR1—muscle cancer	2.93e-06	0.000727	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—MED12—muscle cancer	2.85e-06	0.000707	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IGF2—muscle cancer	2.8e-06	0.000695	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ENO2—muscle cancer	2.75e-06	0.000682	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IGF2—muscle cancer	2.74e-06	0.00068	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IGF2—muscle cancer	2.7e-06	0.00067	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTCH1—muscle cancer	2.65e-06	0.000659	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTCH1—muscle cancer	2.61e-06	0.000649	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTCH1—muscle cancer	2.61e-06	0.000647	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ENO2—muscle cancer	2.6e-06	0.000645	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—FOXO1—muscle cancer	2.57e-06	0.000639	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IGF2—muscle cancer	2.57e-06	0.000639	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—FOXO1—muscle cancer	2.52e-06	0.000626	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—FOXO1—muscle cancer	2.48e-06	0.000616	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—FH—muscle cancer	2.48e-06	0.000616	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IGF2—muscle cancer	2.43e-06	0.000603	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IGF2—muscle cancer	2.39e-06	0.000595	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—FOXO1—muscle cancer	2.37e-06	0.000588	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—MED12—muscle cancer	2.33e-06	0.000579	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	2.31e-06	0.000574	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—FOXO4—muscle cancer	2.28e-06	0.000567	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—MED12—muscle cancer	2.27e-06	0.000565	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—FOXO4—muscle cancer	2.25e-06	0.000558	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—FOXO4—muscle cancer	2.24e-06	0.000557	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CNR1—muscle cancer	2.24e-06	0.000557	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—FOXO1—muscle cancer	2.23e-06	0.000555	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CNR1—muscle cancer	2.2e-06	0.000548	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—FOXO1—muscle cancer	2.2e-06	0.000547	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CNR1—muscle cancer	2.2e-06	0.000547	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—MED12—muscle cancer	2.14e-06	0.000532	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—MED12—muscle cancer	2.12e-06	0.000528	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ENO2—muscle cancer	2.12e-06	0.000528	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ENO2—muscle cancer	2.07e-06	0.000515	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.03e-06	0.000504	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KIT—muscle cancer	1.96e-06	0.000487	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ENO2—muscle cancer	1.95e-06	0.000485	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ENO2—muscle cancer	1.94e-06	0.000481	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KIT—muscle cancer	1.92e-06	0.000477	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KIT—muscle cancer	1.89e-06	0.00047	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IGF2—muscle cancer	1.83e-06	0.000455	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—MED12—muscle cancer	1.82e-06	0.000451	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KIT—muscle cancer	1.8e-06	0.000448	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IGF2—muscle cancer	1.8e-06	0.000448	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IGF2—muscle cancer	1.8e-06	0.000447	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KIT—muscle cancer	1.7e-06	0.000423	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—FOXO1—muscle cancer	1.69e-06	0.000419	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KIT—muscle cancer	1.68e-06	0.000417	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.66e-06	0.000413	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—FOXO1—muscle cancer	1.66e-06	0.000412	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—FOXO1—muscle cancer	1.66e-06	0.000411	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ENO2—muscle cancer	1.65e-06	0.000411	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PTGS2—muscle cancer	1.57e-06	0.000391	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MDM2—muscle cancer	1.54e-06	0.000384	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.51e-06	0.000376	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MDM2—muscle cancer	1.51e-06	0.000376	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MDM2—muscle cancer	1.49e-06	0.00037	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MDM2—muscle cancer	1.42e-06	0.000353	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—MED12—muscle cancer	1.4e-06	0.000348	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MDM2—muscle cancer	1.34e-06	0.000333	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTGS2—muscle cancer	1.32e-06	0.000329	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MDM2—muscle cancer	1.32e-06	0.000328	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.29e-06	0.000322	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KIT—muscle cancer	1.28e-06	0.000319	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ENO2—muscle cancer	1.28e-06	0.000317	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KIT—muscle cancer	1.26e-06	0.000314	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KIT—muscle cancer	1.26e-06	0.000313	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—VEGFA—muscle cancer	1.17e-06	0.000291	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—VEGFA—muscle cancer	1.15e-06	0.000285	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—VEGFA—muscle cancer	1.13e-06	0.000281	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—VEGFA—muscle cancer	1.08e-06	0.000268	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—muscle cancer	1.02e-06	0.000253	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MDM2—muscle cancer	1.01e-06	0.000251	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—muscle cancer	1e-06	0.000249	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MDM2—muscle cancer	9.95e-07	0.000247	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MDM2—muscle cancer	9.93e-07	0.000247	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—muscle cancer	9.57e-07	0.000238	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—muscle cancer	9.04e-07	0.000225	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—muscle cancer	8.86e-07	0.00022	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—muscle cancer	8.68e-07	0.000216	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—muscle cancer	8.54e-07	0.000212	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—muscle cancer	8.15e-07	0.000203	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—muscle cancer	7.69e-07	0.000191	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—muscle cancer	7.68e-07	0.000191	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—muscle cancer	7.59e-07	0.000188	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—muscle cancer	7.56e-07	0.000188	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—muscle cancer	7.54e-07	0.000187	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—muscle cancer	7.4e-07	0.000184	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—muscle cancer	7.22e-07	0.000179	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—muscle cancer	6.8e-07	0.000169	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—muscle cancer	6.75e-07	0.000168	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—muscle cancer	5.8e-07	0.000144	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—muscle cancer	5.76e-07	0.000143	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—muscle cancer	5.71e-07	0.000142	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—muscle cancer	5.7e-07	0.000142	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—muscle cancer	4.45e-07	0.000111	CbGpPWpGaD
